A Double-blind (Within Dose Groups), Randomised, Placebo-controlled Single Increasing Dose Safety, Tolerability and Pharmacokinetics Study (Parallel Groups) in Healthy Male and Female Volunteers After Oral Administration of BIBN 4096 BS Drinking Solution (Dosage: 20 - 200 mg)

Boehringer Ingelheim0 个研究点目标入组 32 人2000年10月

适应症Healthy

干预措施BIBN 4096 BS - in single rising doses Placebo

概览

阶段: 1 期
干预措施: BIBN 4096 BS - in single rising doses
疾病 / 适应症: Healthy
发起方: Boehringer Ingelheim
入组人数: 32
主要终点: Number of patients with adverse events
状态: 已完成
最后更新: 11年前

概览研究者入排标准研究组 & 干预措施结局指标相似试验

概览

简要总结

The objective of the present study was to obtain information about safety, tolerability and pharmacokinetics of BIBN 4096 BS after oral administration of increasing doses in healthy male and female volunteers. With respect to pharmacokinetics, it was of particular importance to investigate whether therapeutic plasma levels (for treatment of migraine) could have been achieved by oral administration of a BIBN 4096 BS formulation.

注册库

clinicaltrials.gov

开始日期

2000年10月

结束日期

2000年12月

最后更新

11年前

研究类型

Interventional

研究设计

Parallel

性别

All

研究者

发起方

Boehringer Ingelheim

责任方

Sponsor

入排标准

入选标准

•Participants should be healthy males and females
•Age range from 21 to 50 years
•Broca Index: within +- 20% of their normal weight
•Subsequently each subject will have his medical history taken and will receive a complete medical examination (incl. blood pressure and pulse rate measurements) as well as a 12-lead Electrocardiogram (ECG). Hematopoietic, hepatic and renal function test will be carried out in the laboratory. The subjects will fast for 12 hours before collection of specimens for all laboratory evaluations. The above mentioned examinations will be performed within 14 days before the first administration of the test substance. In accordance with Good Clinical Practice (GCP) and local legislation all volunteers will have given their written informed consent prior to admission to the study

排除标准

•Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
•Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
•Diseases of the central nervous system (such as epilepsy) or with psychiatric disorders or neurological disorders
•History of orthostatic hypotension, fainting spells or blackouts
•Chronic or relevant acute infections
•History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
•Intake of drugs with a long half-life (\>24 hours) within at least one month or less than ten half-lives of the respective drug before enrolment in the study (exclusion: substitution therapy regarding thyroid gland and/or ovaries)
•Use of any drugs which might influence the results of the trial (within one week prior to administration or during the trial)
•Participation in another study with an investigational drug within two months prior to administration or during the trial
•Smoker (\> 10 cigarettes or \> 3 cigars or \> 3 pipes/day)

研究组 & 干预措施

BIBN 4096 BS - in single rising doses

干预措施: BIBN 4096 BS - in single rising doses

Placebo

干预措施: Placebo

结局指标

主要结局

Number of patients with adverse events

时间窗: up to 24 days

Number of patients with abnormal changes in laboratory parameters

时间窗: up to 8 days after drug administration

Number of patients with clinically significant changes in vital signs (blood pressure, pulse rate)

时间窗: up to 8 days after drug administration

Number of patients with clinically significant changes in 12-lead Electrocardiogram (ECG)

时间窗: up to 8 days after drug administration

次要结局

AUC0-∞ (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)(up to 24 hours after drug administration)
CL/F (Apparent clearance of the analyte in plasma following extravascular administration)(up to 24 hours after drug administration)
MRTtot (Total mean residence time of the analyte in plasma)(up to 24 hours after drug administration)
Vz/F (Apparent volume of distribution of the analyte during the terminal phase)(up to 24 hours after drug administration)
AUC0-tz (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)(up to 24 hours after drug administration)
Terminal rate constant in plasma(up to 24 hours after drug administration)
tmax (Time from dosing to the maximum concentration of the analyte in plasma)(up to 24 hours after drug administration)
Cmax (Maximum measured concentration of the analyte in plasma)(up to 24 hours after drug administration)
t½ (Terminal half-life of the analyte in plasma)(up to 24 hours after drug administration)